Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race
Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants (none had diabetes, but all had weight-related health issues) and randomly assigned them to various daily doses of the pill or a placebo for 72 weeks reuters.com. The outcomes were encouraging yet mixed. Patients on the highest dose (36 mg daily) lost on average about 11–12% of their starting body weight by week 72 theguardian.com. In practical terms, that’s roughly